查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1631234

CGRP抑制劑的全球市場 - 全球產業分析，規模，佔有率，成長，趨勢，預測(2032年)

CGRP Inhibitors Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032
出版日期: | 出版商: Fairfield Market Research | 英文 213 Pages | 商品交期: 2-5個工作天內

價格
簡介目錄

由於全球偏頭痛盛行率不斷上升，全球 CGRP 抑制劑市場規模的需求正在激增。這些抑制劑是突破性的藥物，針對的是降鈣素基因相關胜肽 (CGRP)，這是偏頭痛發展的關鍵治療標靶。透過抑制 CGRP 的活性，它可以顯著降低偏頭痛的發作頻率和嚴重程度。預計複合年增長率 (CAGR) 為 13.90%，該市場預計將實現大幅增長，提供有針對性的有效解決方案，重塑偏頭痛管理並改善全球數百萬人的生活品質。

CGRP 抑制劑透過調節降鈣素基因相關胜肽 (CGRP) 的活性發揮作用，降鈣素基因相關胜肽是一種在偏頭痛發病機制中發揮重要作用的神經肽。透過阻止 CGRP 與其受體結合或抑制其釋放，這些抑制劑可顯著降低偏頭痛的頻率和嚴重程度。作為慢性偏頭痛的預防治療，CGRP 抑制劑正在重塑這種使人衰弱的疾病的治療分析。

受偏頭痛藥物的進步以及患者和醫療保健提供者認識的提高的推動，CGRP 抑制劑的全球市場預計將出現顯著增長。憑藉創新的解決方案和策略合作夥伴關係，市場參與者能夠很好地滿足對有效偏頭痛治療日益增長的需求。隨著認識的不斷深入，CGRP 抑制劑不斷重新定義偏頭痛管理的標準，為全球數百萬人帶來希望和生活品質的改善。

全球偏頭痛的增加使得需要有針對性的治療幹預，從而推動了對 CGRP 抑制劑的需求。與傳統治療方法相比，CGRP抑制劑的標靶機制具有較高的療效和良好的安全性，因此增加了其採用率。 CGRP抑制劑的出現凸顯了偏頭痛治療的典範轉移，強調精準和個人化醫療。醫療保健提供者越來越多地支持預防性偏頭痛治療，因為他們認識到其對患者的長期益處並減少對止痛藥的依賴。宣傳活動和教育措施在向患者介紹先進的偏頭痛治療方案方面發揮關鍵作用，進一步推動了對 CGRP 抑制劑的需求。

本報告提供全球CGRP抑制劑市場相關調查，提供市場概要，以及各分子，不同治療，各給藥途徑，各最終用途，及各地區趨勢，及市場參與市場企業的競爭趨勢等資訊。

目錄

第1章 摘要整理

第2章 市場概要

  • 市場定義和市場區隔
  • 市場動態
  • 價值鏈分析
  • 波特的五力分析
  • COVID-19影響分析
  • 烏克蘭·俄羅斯糾紛的影響
  • 經濟概要
  • 大環境分析

第3章 產量與貿易統計，2019年～2023年

第4章 價格分析，2019年～2023年

第5章 全球CGRP抑制劑市場預測，2019年～2032年

  • 全球CGRP抑制劑市場預測，各分子，金額(10億美元)，數量(100萬個)，2019年～2032年
  • 全球CGRP抑制劑市場預測，不同治療，金額(10億美元)，數量(100萬個)，2019年～2032年
  • 全球CGRP抑制劑市場預測，各給藥途徑，金額(10億美元)，數量(100萬個)，2019年～2032年
  • 全球CGRP抑制劑市場預測，各最終用途，金額(10億美元)，數量(100萬個)，2019年～2032年
  • 全球CGRP抑制劑市場預測，各地區，金額(10億美元)，數量(100萬個)，2019年～2032年

第6章 北美的CGRP抑制劑市場預測，2019年～2032年

第7章 歐洲的CGRP抑制劑市場預測，2019年～2032年

第8章 亞太地區的CGRP抑制劑市場預測，2019年～2032年

第9章 南美的CGRP抑制劑市場預測，2019年～2032年

第10章 中東·非洲的CGRP抑制劑市場預測，2019年～2032年

第11章 競爭情形

  • 各給藥途徑和不同治療熱圖
  • 各製造廠商和不同治療熱圖
  • 企業市場佔有率分析，2022年
  • 競爭儀表板
  • 企業簡介
    • Amgen
    • Novartis
    • Teva Pharmaceutical Industries Ltd.
    • Eli Lilly
    • Lundbeck
    • Abbvie
    • Allergan

第12章 附錄

簡介目錄

The global CGRP inhibitors market is experiencing a surge in demand due to the rising prevalence of migraines worldwide. These inhibitors, a groundbreaking class of pharmaceuticals, target the calcitonin gene-related peptide (CGRP), a key player in migraine development. By preventing CGRP activity, they significantly reduce the frequency and severity of migraines. With a projected compound annual growth rate (CAGR) of 13.90%, the market is poised to achieve substantial growth, offering targeted and effective solutions that are reshaping migraine management and improving the quality of life for millions globally.

Market Insights

CGRP inhibitors work by modulating the activity of the calcitonin gene-related peptide (CGRP), a neuropeptide that plays a significant role in migraine pathogenesis. By preventing CGRP from binding to its receptors or blocking its release, these inhibitors significantly reduce migraine frequency and severity. As preventive treatments for chronic migraines, CGRP inhibitors are reshaping the therapeutic Analysis for this debilitating condition.

The global CGRP inhibitors market is set to witness significant growth, driven by advancements in migraine therapeutics and increasing awareness among patients and healthcare providers. With innovative solutions and strategic collaborations, the market players are well-positioned to address the growing demand for effective migraine treatments. As the Analysis evolves, CGRP inhibitors continue to redefine the standards of care in migraine management, offering hope and improved quality of life for millions worldwide.

Key Market Drivers

  • Rising Migraine Prevalence: The growing global burden of migraines necessitates targeted therapeutic interventions, driving the demand for CGRP inhibitors.
  • Effectiveness and Precision: The targeted mechanism of CGRP inhibitors offers higher efficacy and better safety profiles compared to traditional treatments, increasing their adoption.
  • Advancements in Migraine Care: The emergence of CGRP inhibitors underscores a paradigm shift in migraine therapeutics, emphasizing precision medicine and personalized care.
  • Shifting Treatment Paradigms: Healthcare providers are increasingly favoring preventive migraine treatments, recognizing their long-term benefits for patients and reducing reliance on pain-relief medications.
  • Growing Awareness Among Patients: Awareness campaigns and educational initiatives have played a pivotal role in informing patients about advanced migraine treatment options, further driving demand for CGRP inhibitors.

Business Opportunities

  • Combination Therapies: Exploring combination treatments involving CGRP inhibitors and other migraine management modalities presents a promising avenue for innovation and revenue growth.
  • Strategic Partnerships: Collaborations between pharmaceutical companies, healthcare institutions, and research organizations can enhance awareness, accessibility, and affordability of CGRP inhibitors.
  • Patient-Centric Solutions: Developing non-invasive and patient-friendly delivery methods, such as nasal sprays, can further expand the market reach.

Regional Analysis

  • Europe: As the leading region, Europe is driving market growth through strategic healthcare initiatives, a robust regulatory framework, and a strong focus on advanced migraine therapies.
  • South Asia & Pacific: This region is the fastest-growing market, supported by a rising migraine burden, increased awareness of innovative treatments, and improved healthcare access.
  • North America: The region's advanced healthcare infrastructure and high adoption rates for innovative therapies position it as a critical market for CGRP inhibitors.

Key Players

Prominent companies in the CGRP inhibitors market include:

  • Amgen
  • Novartis
  • Teva Pharmaceutical Industries Ltd.
  • Eli Lilly
  • Lundbeck
  • Abbvie
  • Allergan

These organizations are at the forefront of research and development, introducing innovative therapies and expanding their product portfolios to maintain a competitive edge.

Market Segmentation

1. By Molecule:

    Small Molecule Large Molecule

2. By Treatment:

    Preventive Migraine Treatment Acute Migraine Treatment

3. By Route of Administration:

    Oral Nasal Injectables

4. By End-Use:

    Hospitals Specialty Clinics Mail Order Pharmacies Retail Pharmacies

5. By Region:

    North America Europe Asia Pacific Latin America Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Global CGRP Inhibitors Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Volume and Value, 2024
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. Porter's Five Forces Analysis
  • 2.5. Covid-19 Impact Analysis
    • 2.5.1. Supply
    • 2.5.2. Demand
  • 2.6. Impact Of Ukraine-Russia Conflict
  • 2.7. Economic Overview
    • 2.7.1. World Economic Projections
  • 2.8. Pestle Analysis

3. Production Output and Trade Statistics, 2019 - 2023

  • 3.1. Global CGRP Inhibitors Market Production Output, by Region, Value (US$ Bn) and Volume (Million Units),2019 - 2023
    • 3.1.1. North America
    • 3.1.2. Europe
    • 3.1.3. Asia Pacific
    • 3.1.4. Latin America
    • 3.1.5. Middle East and Africa

4. Price Analysis, 2019 - 2023

  • 4.1. Global Average Price Analysis, by Type, US$ Per Unit, 2019 - 2023
  • 4.2. Prominent Factor Affecting CGRP Inhibitors Prices
  • 4.3. Global Average Price Analysis, by Region, US$ Per Unit, 2019 - 2023

5. Global CGRP Inhibitors Market Outlook, 2019 - 2032

  • 5.1. Global CGRP Inhibitors Market Outlook, by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 5.1.1. Key Highlights
      • 5.1.1.1. Small Molecule
      • 5.1.1.2. Large Molecule
  • 5.2. Global CGRP Inhibitors Market Outlook, by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 5.2.1. Key Highlights
      • 5.2.1.1. Preventive Migraine Treatment
      • 5.2.1.2. Acute Migraine Treatment
  • 5.3. Global CGRP Inhibitors Market Outlook, by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 5.3.1. Key Highlights
      • 5.3.1.1. Oral
      • 5.3.1.2. Nasal
      • 5.3.1.3. Injectables
  • 5.4. Global CGRP Inhibitors Market Outlook, by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 5.4.1. Key Highlights
      • 5.4.1.1. Hospitals
      • 5.4.1.2. Specialty Clinics
      • 5.4.1.3. Mail Order Pharmacies
      • 5.4.1.4. Retail Pharmacies
  • 5.5. Global CGRP Inhibitors Market Outlook, by Region, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 5.5.1. Key Highlights
      • 5.5.1.1. North America
      • 5.5.1.2. Europe
      • 5.5.1.3. Asia Pacific
      • 5.5.1.4. Latin America
      • 5.5.1.5. Middle East & Africa

6. North America CGRP Inhibitors Market Outlook, 2019 - 2032

  • 6.1. North America CGRP Inhibitors Market Outlook, by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 6.1.1. Key Highlights
      • 6.1.1.1. Small Molecule
      • 6.1.1.2. Large Molecule
  • 6.2. North America CGRP Inhibitors Market Outlook, by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 6.2.1. Key Highlights
      • 6.2.1.1. Preventive Migraine Treatment
      • 6.2.1.2. Acute Migraine Treatment
  • 6.3. North America CGRP Inhibitors Market Outlook, by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 6.3.1. Key Highlights
      • 6.3.1.1. Oral
      • 6.3.1.2. Nasal
      • 6.3.1.3. Injectables
  • 6.4. North America CGRP Inhibitors Market Outlook, by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 6.4.1. Key Highlights
      • 6.4.1.1. Hospitals
      • 6.4.1.2. Specialty Clinics
      • 6.4.1.3. Mail Order Pharmacies
      • 6.4.1.4. Retail Pharmacies
  • 6.5. North America CGRP Inhibitors Market Outlook, by Country, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 6.5.1. Key Highlights
      • 6.5.1.1. U.S. CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 6.5.1.2. U.S. CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 6.5.1.3. U.S. CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 6.5.1.4. U.S. CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 6.5.1.5. Canada CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 6.5.1.6. Canada CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 6.5.1.7. Canada CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 6.5.1.8. Canada CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 6.5.2. BPS Analysis/Market Attractiveness Analysis

7. Europe CGRP Inhibitors Market Outlook, 2019 - 2032

  • 7.1. Europe CGRP Inhibitors Market Outlook, by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 7.1.1. Key Highlights
      • 7.1.1.1. Small Molecule
      • 7.1.1.2. Large Molecule
  • 7.2. Europe CGRP Inhibitors Market Outlook, by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 7.2.1. Key Highlights
      • 7.2.1.1. Preventive Migraine Treatment
      • 7.2.1.2. Acute Migraine Treatment
  • 7.3. Europe CGRP Inhibitors Market Outlook, by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 7.3.1. Key Highlights
      • 7.3.1.1. Oral
      • 7.3.1.2. Nasal
      • 7.3.1.3. Injectables
  • 7.4. Europe CGRP Inhibitors Market Outlook, by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 7.4.1. Key Highlights
      • 7.4.1.1. Hospitals
      • 7.4.1.2. Specialty Clinics
      • 7.4.1.3. Mail Order Pharmacies
      • 7.4.1.4. Retail Pharmacies
  • 7.5. Europe CGRP Inhibitors Market Outlook, by Country, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 7.5.1. Key Highlights
      • 7.5.1.1. Germany CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.2. Germany CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.3. Germany CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.4. Germany CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.5. U.K. CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.6. U.K. CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.7. U.K. CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.8. U.K. CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.9. France CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.10. France CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.11. France CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.12. France CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.13. Italy CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.14. Italy CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.15. Italy CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.16. Italy CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.17. Turkey CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.18. Turkey CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.19. Turkey CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.20. Turkey CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.21. Russia CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.22. Russia CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.23. Russia CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.24. Russia CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.25. Rest Of Europe CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.26. Rest Of Europe CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.27. Rest Of Europe CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.28. Rest of Europe CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 7.5.2. BPS Analysis/Market Attractiveness Analysis

8. Asia Pacific CGRP Inhibitors Market Outlook, 2019 - 2032

  • 8.1. Asia Pacific CGRP Inhibitors Market Outlook, by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 8.1.1. Key Highlights
      • 8.1.1.1. Small Molecule
      • 8.1.1.2. Large Molecule
  • 8.2. Asia Pacific CGRP Inhibitors Market Outlook, by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 8.2.1. Key Highlights
      • 8.2.1.1. Preventive Migraine Treatment
      • 8.2.1.2. Acute Migraine Treatment
  • 8.3. Asia Pacific CGRP Inhibitors Market Outlook, by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 8.3.1. Key Highlights
      • 8.3.1.1. Oral
      • 8.3.1.2. Nasal
      • 8.3.1.3. Injectables
  • 8.4. Asia Pacific CGRP Inhibitors Market Outlook, by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 8.4.1. Key Highlights
      • 8.4.1.1. Hospitals
      • 8.4.1.2. Specialty Clinics
      • 8.4.1.3. Mail Order Pharmacies
      • 8.4.1.4. Retail Pharmacies
  • 8.5. Asia Pacific CGRP Inhibitors Market Outlook, by Country, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 8.5.1. Key Highlights
      • 8.5.1.1. China CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.2. China CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.3. China CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.4. China CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.5. Japan CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.6. Japan CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.7. Japan CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.8. Japan CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.9. South Korea CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.10. South Korea CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.11. South Korea CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.12. South Korea CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.13. India CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.14. India CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.15. India CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.16. India CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.17. Southeast Asia CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.18. Southeast Asia CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.19. Southeast Asia CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.20. Southeast Asia CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.21. Rest Of Asia Pacific CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.22. Rest Of Asia Pacific CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.23. Rest Of Asia Pacific CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.24. Rest of Asia CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 8.5.2. BPS Analysis/Market Attractiveness Analysis

9. Latin America CGRP Inhibitors Market Outlook, 2019 - 2032

  • 9.1. Latin America CGRP Inhibitors Market Outlook, by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 9.1.1. Key Highlights
      • 9.1.1.1. Small Molecule
      • 9.1.1.2. Large Molecule
  • 9.2. Latin America CGRP Inhibitors Market Outlook, by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 9.2.1. Key Highlights
      • 9.2.1.1. Preventive Migraine Treatment
      • 9.2.1.2. Acute Migraine Treatment
  • 9.3. Latin America CGRP Inhibitors Market Outlook, by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 9.3.1. Key Highlights
      • 9.3.1.1. Oral
      • 9.3.1.2. Nasal
      • 9.3.1.3. Injectables
  • 9.4. Latin America CGRP Inhibitors Market Outlook, by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 9.4.1. Key Highlights
      • 9.4.1.1. Hospitals
      • 9.4.1.2. Specialty Clinics
      • 9.4.1.3. Mail Order Pharmacies
      • 9.4.1.4. Retail Pharmacies
  • 9.5. Latin America CGRP Inhibitors Market Outlook, by Country, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 9.5.1. Key Highlights
      • 9.5.1.1. Brazil CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.2. Brazil CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.3. Brazil CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.4. Brazil CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.5. Mexico CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.6. Mexico CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.7. Mexico CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.8. Mexico CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.9. Argentina CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.10. Argentina CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.11. Argentina CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.12. Argentina CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.13. Rest Of Latin America CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.14. Rest Of Latin America CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.15. Rest Of Latin America CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.16. Rest of Latin America CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 9.5.2. BPS Analysis/Market Attractiveness Analysis

10. Middle East & Africa CGRP Inhibitors Market Outlook, 2019 - 2032

  • 10.1. Middle East & Africa CGRP Inhibitors Market Outlook, by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 10.1.1. Key Highlights
      • 10.1.1.1. Small Molecule
      • 10.1.1.2. Large Molecule
  • 10.2. Middle East & Africa CGRP Inhibitors Market Outlook, by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 10.2.1. Key Highlights
      • 10.2.1.1. Preventive Migraine Treatment
      • 10.2.1.2. Acute Migraine Treatment
  • 10.3. Middle East & Africa CGRP Inhibitors Market Outlook, by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 10.3.1. Key Highlights
      • 10.3.1.1. Oral
      • 10.3.1.2. Nasal
      • 10.3.1.3. Injectables
  • 10.4. Middle East & Africa CGRP Inhibitors Market Outlook, by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 10.4.1. Key Highlights
      • 10.4.1.1. Hospitals
      • 10.4.1.2. Specialty Clinics
      • 10.4.1.3. Mail Order Pharmacies
      • 10.4.1.4. Retail Pharmacies
  • 10.5. Middle East & Africa CGRP Inhibitors Market Outlook, by Country, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 10.5.1. Key Highlights
      • 10.5.1.1. GCC CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 10.5.1.2. GCC CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 10.5.1.3. GCC CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 10.5.1.4. GCC CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 10.5.1.5. South Africa CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 10.5.1.6. South Africa CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 10.5.1.7. South Africa CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 10.5.1.8. South Africa CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 10.5.1.9. Egypt CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 10.5.1.10. Egypt CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 10.5.1.11. Egypt CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 10.5.1.12. Egypt CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 10.5.1.13. Nigeria CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 10.5.1.14. Nigeria CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 10.5.1.15. Nigeria CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 10.5.1.16. Nigeria CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 10.5.1.17. Rest Of Middle East & Africa CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 10.5.1.18. Rest Of Middle East & Africa CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 10.5.1.19. Rest Of Middle East & Africa CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 10.5.1.20. Rest of Middle East & Africa CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 10.5.2. BPS Analysis/Market Attractiveness Analysis

11. Competitive Landscape

  • 11.1. By Route of Administration Vs by Treatment Heat Map
  • 11.2. Manufacturer Vs by Treatment Heatmap
  • 11.3. Company Market Share Analysis, 2022
  • 11.4. Competitive Dashboard
  • 11.5. Company Profiles
    • 11.5.1. Amgen
      • 11.5.1.1. Company Overview
      • 11.5.1.2. Type Portfolio
      • 11.5.1.3. Financial Overview
      • 11.5.1.4. Business Strategies and Development
    • 11.5.2. Novartis
      • 11.5.2.1. Company Overview
      • 11.5.2.2. Type Portfolio
      • 11.5.2.3. Financial Overview
      • 11.5.2.4. Business Strategies and Development
    • 11.5.3. Teva Pharmaceutical Industries Ltd.
      • 11.5.3.1. Company Overview
      • 11.5.3.2. Type Portfolio
      • 11.5.3.3. Financial Overview
      • 11.5.3.4. Business Strategies and Development
    • 11.5.4. Eli Lilly
      • 11.5.4.1. Company Overview
      • 11.5.4.2. Type Portfolio
      • 11.5.4.3. Financial Overview
      • 11.5.4.4. Business Strategies and Development
    • 11.5.5. Lundbeck
      • 11.5.5.1. Company Overview
      • 11.5.5.2. Type Portfolio
      • 11.5.5.3. Financial Overview
      • 11.5.5.4. Business Strategies and Development
    • 11.5.6. Abbvie
      • 11.5.6.1. Company Overview
      • 11.5.6.2. Type Portfolio
      • 11.5.6.3. Financial Overview
      • 11.5.6.4. Business Strategies and Development
    • 11.5.7. Allergan
      • 11.5.7.1. Company Overview
      • 11.5.7.2. Type Portfolio
      • 11.5.7.3. Financial Overview
      • 11.5.7.4. Business Strategies and Development

12. Appendix

  • 12.1. Research Methodology
  • 12.2. Report Assumptions
  • 12.3. Acronyms And Abbreviations